Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.

Gampenrieder, SP, Hufnagl, C, Brechelmacher, S, Huemer, F, Hackl, H, Rinnerthaler, G, Romeder, F, Monzo Fuentes, C, Morre, P, Hauser-Kronberger, C, Mlineritsch, B, Greil, R.

http://www.ncbi.nlm.nih.gov/pubmed/27139155